JNJ vs OABI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
OABI presents a contradictory profile: while the Piotroski F-Score of 6/9 indicates stable financial health and the balance sheet is strong with low debt and high liquidity, the operational data is alarming. Revenue is declining sharply (-22.5% YoY), and the stock is in a severe technical downtrend with bearish insider activity from the CEO and CFO. Despite a 'Strong Buy' analyst consensus and a high price target, the fundamental divergence between shrinking top-line growth and high Price/Sales valuation suggests significant risk.
Compare Another Pair
Related Comparisons
JNJ vs OABI: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and OmniAb, Inc. (OABI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.